554 related articles for article (PubMed ID: 26099671)
1. Impact of Fluorodeoxyglucose PET/Computed Tomography on the Management of Patients with Colorectal Cancer.
Laurens ST; Oyen WJ
PET Clin; 2015 Jul; 10(3):345-60. PubMed ID: 26099671
[TBL] [Abstract][Full Text] [Related]
2. [18F]Fluorodeoxyglucose PET/Computed Tomography in Gastrointestinal Malignancies.
Donswijk ML; Hess S; Mulders T; Lam MG
PET Clin; 2014 Oct; 9(4):421-41, v-vi. PubMed ID: 26050945
[TBL] [Abstract][Full Text] [Related]
3. Clinical impact of FDG PET-CT in patients with potentially operable metastatic colorectal cancer.
Briggs RH; Chowdhury FU; Lodge JP; Scarsbrook AF
Clin Radiol; 2011 Dec; 66(12):1167-74. PubMed ID: 21867996
[TBL] [Abstract][Full Text] [Related]
4. Clinical impact of fluorodeoxyglucose-positron emission tomography scan/computed tomography in comparison with computed tomography on the detection of colorectal cancer recurrence.
Deleau C; Buecher B; Rousseau C; Kraeber-Bodéré F; Flamant M; des Varannes SB; Frampas E; Galmiche JP; Matysiak-Budnik T
Eur J Gastroenterol Hepatol; 2011 Mar; 23(3):275-81. PubMed ID: 21304319
[TBL] [Abstract][Full Text] [Related]
5. The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases.
Wiering B; Krabbe PF; Jager GJ; Oyen WJ; Ruers TJ
Cancer; 2005 Dec; 104(12):2658-70. PubMed ID: 16315241
[TBL] [Abstract][Full Text] [Related]
6. [Evaluation of positron emission tomography by using F-18-fluorodeoxyglucose in diagnosis of recurrent colorectal cancer].
Kula Z; Szefer J; Zuchora Z; Romanowicz G; Pietrzak T
Pol Merkur Lekarski; 2004; 17 Suppl 1():63-6. PubMed ID: 15603351
[TBL] [Abstract][Full Text] [Related]
7. Imaging features of colorectal liver metastasis in FDG PET-CT: a retrospective correlative analysis between CT attenuation and FDG uptake.
Au-Yeung AW; Luk WH; Lo AX
Nucl Med Commun; 2012 Apr; 33(4):403-7. PubMed ID: 22273638
[TBL] [Abstract][Full Text] [Related]
8. Can (18)F-FDG PET/CT scan change treatment planning and be prognostic in recurrent colorectal carcinoma? A prospective and follow-up study.
Artiko V; Odalovic S; Sobic-Saranovic D; Petrovic M; Stojiljkovic M; Petrovic N; Kozarevic N; Grozdic-Milojevic I; Obradovic V
Hell J Nucl Med; 2015; 18(1):35-41. PubMed ID: 25840571
[TBL] [Abstract][Full Text] [Related]
9. The influence of FDG PET-CT on the detection of extrahepatic disease in patients being considered for resection of colorectal liver metastasis.
Lake ES; Wadhwani S; Subar D; Kauser A; Harris C; Chang D; Lapsia S
Ann R Coll Surg Engl; 2014 Apr; 96(3):211-5. PubMed ID: 24780786
[TBL] [Abstract][Full Text] [Related]
10. [¹⁸F-FDG PET/CT. Its correlation with carcinoembryonic antigen in patients with colorectal carcinoma].
Granados Rangel O; Estrada G; Altamirano J
Gac Med Mex; 2014; 150(6):509-17. PubMed ID: 25375281
[TBL] [Abstract][Full Text] [Related]
11. The role of 18F-FDG PET/CT in detecting colorectal cancer recurrence in patients with elevated CEA levels.
Ozkan E; Soydal C; Araz M; Kir KM; Ibis E
Nucl Med Commun; 2012 Apr; 33(4):395-402. PubMed ID: 22367859
[TBL] [Abstract][Full Text] [Related]
12. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G
Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
[TBL] [Abstract][Full Text] [Related]
13. The value of FDG positron emission tomography/computerised tomography (PET/CT) in pre-operative staging of colorectal cancer: a systematic review and economic evaluation.
Brush J; Boyd K; Chappell F; Crawford F; Dozier M; Fenwick E; Glanville J; McIntosh H; Renehan A; Weller D; Dunlop M
Health Technol Assess; 2011 Sep; 15(35):1-192, iii-iv. PubMed ID: 21958472
[TBL] [Abstract][Full Text] [Related]
14. FDG-PET for detecting local tumor recurrence of ablated liver metastases: a diagnostic meta-analysis.
Poulou LS; Ziakas PD; Ziogas DC; Doxani C; Xyla V; Vakrinos G; Voulgarelis M; Thanos L
Biomarkers; 2012 Sep; 17(6):532-8. PubMed ID: 22712479
[TBL] [Abstract][Full Text] [Related]
15. FDG PET/CT in Pancreatic and Hepatobiliary Carcinomas: Value to Patient Management and Patient Outcomes.
Parikh U; Marcus C; Sarangi R; Taghipour M; Subramaniam RM
PET Clin; 2015 Jul; 10(3):327-43. PubMed ID: 26099670
[TBL] [Abstract][Full Text] [Related]
16. PET imaging for evaluation of metastatic colorectal cancer of the liver.
Erturk SM; Ichikawa T; Fujii H; Yasuda S; Ros PR
Eur J Radiol; 2006 May; 58(2):229-35. PubMed ID: 16457980
[TBL] [Abstract][Full Text] [Related]
17. FDG PET and PET/CT for colorectal cancer.
Delbeke D; Martin WH
Methods Mol Biol; 2011; 727():77-103. PubMed ID: 21331930
[TBL] [Abstract][Full Text] [Related]
18. Clinical impact of 18F-FDG-PET in the suspicion of recurrent colorectal cancer based on asymptomatically elevated serum level of carcinoembryonic antigen (CEA) in Taiwan.
Shen YY; Liang JA; Chen YK; Tsai CY; Kao CH
Hepatogastroenterology; 2006; 53(69):348-50. PubMed ID: 16795969
[TBL] [Abstract][Full Text] [Related]
19. [18F]Fluorodeoxyglucose PET for Interventional Oncology in Liver Malignancy.
Samim M; El-Haddad GE; Molenaar IQ; Prevoo W; van den Bosch MA; Alavi A; Lam MG
PET Clin; 2014 Oct; 9(4):469-95, vi. PubMed ID: 26050948
[TBL] [Abstract][Full Text] [Related]
20. Role of FDG-PET in the diagnosis and treatment of colorectal liver metastases.
Wiering B; Ruers TJ; Oyen WJ
Expert Rev Anticancer Ther; 2004 Aug; 4(4):607-13. PubMed ID: 15270664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]